Common Stock to Begin Trading on a Split-Adjusted Basis at Market Open on Friday, November 1, 2019

STONY BROOK, N.Y., October 31, 2019 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in polymerase chain reaction (PCR)-based DNA manufacturing for product authenticity and traceability solutions, announced today that it will effect a 1-for-40 reverse split of its outstanding common stock effective at 12:01 AM Eastern Time on Friday, November 1, 2019. The Company’s common stock will begin trading on a split-adjusted basis when The Nasdaq Capital Market opens on Friday, November 1, 2019 under the existing symbol “APDN.” Applied DNA’s common stock will trade under a new CUSIP number, #03815U300.

This announcement of the reverse stock split follows the Company’s special meeting of stockholders on October 31, 2019, at which the stockholders approved an amendment to the Company’s certificate of incorporation to implement a reverse split of its common stock, at a ratio in the range of 1-for-15 to 1-for-50 shares, and authorized the Company’s board of directors to determine the specific ratio.

The reverse stock split is intended to increase the per share trading price of Applied DNA’s common stock to satisfy the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”), and the terms of the Nasdaq Hearings Panel (the “Panel”) decision dated October 1, 2019, which requires that the Company evidence compliance with all applicable criteria for continued listing on or before December 31, 2019.

The Company can provide no assurance that the market price of its common stock will sufficiently increase following the reverse stock split to satisfy the Bid Price Requirement. Even if the reverse stock split results in a closing bid price in excess of $1.00 per share, there can be no assurance that the market price of the Company’s common stock following the reverse stock split will remain above the minimum level required to evidence full compliance with that requirement; that is, a closing bid price of at least $1.00 per share for a minimum of ten, but generally not more than 20, consecutive business days. The Company must also evidence compliance with the applicable $2.5 million stockholders’ equity requirement for continued listing on Nasdaq by no later than December 31, 2019, and as such may remain at risk for delisting notwithstanding the reverse stock split and/or timely satisfaction of the Bid Price Requirement.

The reverse stock split will impact all holders of Applied DNA’s common stock uniformly and will not impact any stockholder’s percentage ownership interest in the Company; however, no fractional shares will be issued in connection with the reverse stock split, and any fractional shares resulting from the reverse stock split will be rounded up to the nearest whole share.  Furthermore, the reverse stock split will not affect any stockholder’s proportionate voting power, subject to the treatment of fractional shares.

At the effective time of the reverse stock split, every 40 shares of APDN common stock will convert into one newly issued share of APDN common stock, without any change in the par value of $0.001 per share. The reverse stock split will reduce the number of shares of Applied DNA’s outstanding common stock from 48,015,938 shares to approximately 1,200,399 shares. Proportional adjustments will be made to Applied DNA’s outstanding stock options and outstanding warrants (both publicly-traded and privately held).“The reverse split has had very solid support from stockholders, and from the board of directors. We believe the change in capital structure can strongly benefit our stockholders,” stated Dr. James A. Hayward, Chairman, President and CEO of Applied DNA.

After the effective time of the reverse stock split, stockholders of shares of common stock held in book-entry form or through a bank, broker or other nominee do not need to take any action in connection with the reverse split and will see the impact of the reverse split automatically reflected in their accounts. Beneficial holders are encouraged to contact their bank, broker or nominee for more information. Stockholders of record with shares held in certificate form will receive instructions from Applied DNA’s exchange agent, American Stock Transfer & Trust Company, LLC, regarding how to exchange existing stock certificates for new book-entry statements reflecting the post-reverse split shares of common stock.

Additional information about the reverse stock split can be found in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on October 8, 2019, a copy of which is available at http://www.sec.gov or at the Company’s website at https://adnasprod.wpengine.com/sec-filings/.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and isolation of circulating tumor cells and the development of pre-clinical nucleic acid-based therapeutic drug candidates.Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.

Forward-Looking Statements
The statements made by Applied DNA in this presentation may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to substantial doubt relating to Applied DNA’s ability to continue as a going concern, uncertainties relating to its ability to maintain its NASDAQ listing after December 31, 2019 in light of delisting notices received and its recent hearing, the possibility of failure to make timely payment on its outstanding secured convertible notes and resulting enforcement by noteholders of remedies on collateral which includes substantially all of Applied DNA’s assets, its history of net losses, limited financial resources, limited market acceptance, its ability to penetrate key markets, the uncertainties inherent in research, development, and regulatory approval for Applied DNA’s or its partners’ product candidates, shifting enforcement priorities of U.S. federal laws relating to cannabis, its ability to satisfy the Bid Price Requirement following the reverse stock split discussed herein, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018, as amended, our subsequent quarterly reports on Form 10-Q filed on February 7, 2019, May 9, 2019 and August 13, 2019, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.

Investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, shurry@lhai.com

STONY BROOK – Molecular authentication technologies provider Applied DNA Sciences (ADNAS) has received a Notice of Allowance for a new patent relating to the use of its CertainT marker system on cellulose-based fibres.

The patent, expected to be confirmed in the coming months, is entitled ‘Methods of Marking Cellulosic Products’ and entails tagging a cellulosic material with a nucleic acid that can be tracked throughout the supply chain and authenticated using PCR-based detection techniques.“

We are in commercial stage discussions with some of the world’s largest cellulosic fibre and materials manufacturers for the implementation of our proven CertainT platform,” said Dr. James Hayward, president of Applied DNA.

Newly Allowed Patent Covers use of the CertainT^® Platform in Cellulosic Fibers and Materials including Rayon; Company Currently in Discussions with Leading Manufacturers

STONY BROOK, N.Y. –  October 22, 2019 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing for product authenticity and traceability solutions, announced today that it has received a Notice of Allowance for its U.S. Patent Application No. 15/466,016 (US 2017/0292206) entitled “Methods of Marking Cellulosic Products.” The allowed patent application, which is expected to be issued as a U.S. patent in the next few months, extends the Company’s patent protection for its CertainT platform into cellulosic fibers and materials. The Company has related international patent applications pending in India, the European Union, China and Hong Kong.

The allowed claims cover methods of tagging cellulosic fibers or materials with a nucleic acid (DNA) tag during production and later authenticating the nucleic acid-tagged cellulosic fibers and/or materials via PCR-based detection techniques.

Cellulosic fibers and materials are man-made and are derived from plant-based resources (cellulose).  Notable cellulosic fibers and materials include rayon. The demand for cellulosic fibers and materials is rapidly expanding, with a market size estimated to surpass USD 39 billion by 2024, growing at an annual rate of 9%. ^[1].

“We are in commercial stage discussions with some of the world’s largest cellulosic fiber and materials manufacturers for the implementation of our proven CertainT platform,” said Dr. James Hayward, president and Chief Executive of Applied DNA.  “The newly allowed patent is a significant milestone for the Company as it enhances our intellectual property portfolio and provides potential exclusivity for our CertainT platform in the ever-growing cellulosic fiber and materials market.”

Dr. Hayward continued: “Since many man-made cellulosic materials such as rayon (with component fibers known as lyocell, viscose and modal) are derived from trees, traceability to assure brand claims for responsible sourcing and sustainable claims is important. The CertainT solution assists fiber producers in ensuring the authenticity and traceability of their branded fibers. We have successfully demonstrated the robust performance of the CertainT molecular tag in commercial production environments from fiber to fabric with top-tier rayon manufacturers in both home goods and apparel.”

[1] https://www.marketwatch.com/press-release/2019-24-cellulose-fiber-market-to-register-usd-39-bn-revenue-2019-07-22

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and isolation of circulating tumor cells and the development of pre-clinical nucleic acid-based therapeutic drug candidates.

Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its ability to continue as a going concern, its history of net losses, limited financial resources, limited market acceptance, uncertainties relating to its ability to maintain its NASDAQ listing in light of delisting notices received and its recent hearing, our ability to penetrate key markets, our ability to successfully enter into commercial contracts for the implementation of our CertainT® platform, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018, as amended, our subsequent quarterly reports on Form 10-Q filed on February 7, 2019, May 9, 2019 and August 13, 2019, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.

Investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, shurry@lhai.com
Program contacts: MeiLin Wan, Vice President Textile Sales, 631-240-8849, meilin.wan@adnas.com

Meilin Wan, vice president for textiles at Applied DNA Sciences, will make a presentation on DNA traceability at Leather, Compliance and Sustainability conference on November 13. For over 16 years, Wan has worked in the bioscientific field transforming use of forensic DNA and nanotechnologies into useful and novel consumer and industrial driven applications.

Effective traceability of materials up the supply chain is the best way to manage sustainability risk and mitigate against potential environmental and social challenges. An effective traceability programme can ensure managing out deforestation risk from the supply chain.

Leather can be a particularly challenging material to effectively trace as it is a by-product of a different industry. Traditional methods for marking leather involve stamping, this can be difficult to record as the stamps will ultimately be cut out of any finished product and in some cases the stamp can actually damage the leather material.

By Michelle Russsell

Applied DNA Sciences, a leader in polymerase chain reaction (PCR)-based DNA manufacturing for product authenticity and traceability solutions, has entered into a partnership with Molecular Isotope Technologies (MIT), a pioneer and leader in the application of natural-abundance stable-isotopic analysis provided under the trademarks Nature’s Fingerprint and IsoPedigree.

MIT’s technology utilises stable isotopic “fingerprints” as a method for verification of product origin and supply chain processing to support product claims. For 20 years the company has provided patented services to the bio/pharmaceutical industry, which have been successfully employed in various legal matters, supporting pharmaceutical patent-infringement and fraud lawsuits.

These authentication services are tailored to specific product and supply chain processes and will be offered by Applied DNA as an additional component of its CertainT platform to tag, test and track raw materials and finished goods. MIT will support and promote the CertainT platform as a service complementary to its own.

By Chris Remington

STONY BROOK – Authentication technologies specialist Applied DNA Sciences (ADNAS) has bolstered the efficacy of its tagging CertainT technology by partnering with Molecular Isotope Technologies (MIT LLC), which is able to take isotopic “fingerprints’ of materials to attain their chemical, geographic and industrial provenance.

CertainT Platform Complemented by Stable-Isotopic Indicators Offers Brand Owners Increased Supply Chain Transparency and Product and Process Authentication

STONY BROOK, N.Y. –  October 16, 2019 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA”, the “Company”), a leader in polymerase chain reaction (PCR)-based DNA manufacturing for product authenticity and traceability solutions, announced today that it has entered into a partnership with Molecular Isotope Technologies, LLC (“MIT LLC”), a pioneer and leader in the application of natural-abundance stable-isotopic analysis provided under the trademarks Nature’s Fingerprint^® and IsoPedigree™. MIT LLC’s technology utilizes stable isotopic “fingerprints” as a method for verification of product origin and supply chain processing to support product claims.

For 20 years MIT LLC has provided patented services to the bio/pharmaceutical industry which have been successfully employed in various legal matters, supporting pharmaceutical patent-infringement and fraud lawsuits. These authentication services are tailored to specific product and supply chain processes and will be offered by Applied DNA as an additional component of its CertainT^® platform to tag, test and track raw materials and finished goods. MIT LLC will support and promote the CertainT platform as a service complementary to its own.

“Through the combined power of our cutting-edge technologies, Applied DNA offers brand owners “one-stop-shop” access to unique analytical tools to verify product and process authenticity for brand assurance and provenance with forensic certainty. This partnership with MIT LLC enhances Applied DNA’s CertainT feature-set by offering additional datapoints for deeper product and supply chain intelligence supported by world-class forensic laboratory services. The large-scale tagging and authentication of customer-specific DNA identity at most any supply chain node, combined with genotyping identification allies perfectly with stable-isotopic identification of origin and process. We expect our enhanced portfolio will serve to further our penetration of key markets such as textiles, adding another level of identity for organic cotton, among other natural materials,” stated Judy Murrah, chief information officer of Applied DNA.

Stable-isotopic “fingerprints” within materials provide innate chemical evidence of their chemical, geographic, and industrial provenance and major processing-dependent characteristics. They derive from the natural abundance of various stable isotopes including carbon, nitrogen, oxygen, sulfur and others that vary in their isotopic ratios and are present in soil, water and other organic materials and become integrated with the chemical composition of a product from raw materials through synthetic intermediates to finished products. Discrete process steps may alter isotopic fingerprints, permitting the identification of deviations in locale or materiel. MIT LLC’s existing and pending patents variously encompass the use of natural-abundance stable-isotopic analysis for establishing both product and process fingerprints.

About Molecular Isotope Technologies, LLC
Founded in 1999, Molecular Isotope Technologies (MIT LLC) owns and uses the trademarks Nature’s Fingerprint® and IsoPedigree™. Via highly precise natural-abundance stable-isotopic analysis, MIT LLC significantly contributes to the definition of intellectual-property provenance and to the mitigation of intellectual-property infringement of various organic (e.g., bio/pharmaceutical, agricultural, and other) products and the synthetic pathways by which they were produced. After having established the isotopic provenance and process pathways of various bio/pharmaceutical materials, MIT LLC has provided the isotopic evidence that has protected more than $2 billion of bio/pharmaceutical products.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and isolation of circulating tumor cells and the development of pre-clinical nucleic acid-based therapeutic drug candidates.

Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its ability to continue as a going concern, its history of net losses, limited financial resources, limited market acceptance, uncertainties relating to its ability to maintain its NASDAQ listing in light of delisting notices received and its recent hearing, our ability to penetrate key markets, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018, as amended, our subsequent quarterly reports on Form 10-Q filed on February 7, 2019, May 9, 2019 and August 13, 2019, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.

Investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, shurry@lhai.com
Program contacts: Judy Murrah, Chief Information Officer, 631-240-8819, judy.murrah@adnas.com

International Journal of Pharmaceutics publication evaluates a proprietary method to tag pharmaceutical excipients
Study conducted at King’s College London with Collaborators from Dubai Police and Applied DNA concludes the proprietary method of DNA tagging excipients can mitigate the risks of counterfeit drugs

STONY BROOK, N.Y., October 4, 2019 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA”), a leader in large-scale PCR-based DNA manufacturing, announced today that a scientific paper entitled, ‘Anti-counterfeiting DNA molecular tagging of pharmaceutical excipients: An evaluation of lactose containing tablets’, has been published in the International Journal of Pharmaceutics, detailing a novel Physical-Chemical Identifier (PCID) to authenticate and track legitimate pharmaceutical products through the pharmaceutical supply chain.

The study carried out by a team led by Dr. Royall at the Institute of Pharmaceutical Science, King’s College London and Dr. Altamimi from the Department of Forensic Evidence & Criminology, Dubai Police HQ, UAE, evaluated the use of DNA molecular tags as a potential anti-counterfeiting technology in tablets. Lactose tablets were used as a model of a solid dosage form. Analysis for in-field DNA authentication was carried out using a portable Applied DNA SigNify^® qPCR instrument. Tablet batches were subjected to accelerated stability conditions for 6 months with the DNA tag clearly detected in all tablets after the storage period. All tablet batches passed the monograph specifications of the British Pharmacopoeia throughout the storage period. The study concluded that DNA molecular tags could feasibly be applied within the pharmaceutical development cycle when a new solid dosage form is brought to the market so as to mitigate the risk and dangers of counterfeiting.

“We believe DNA tagging of inks, coatings, and other ingredients are candidates for use in the pharmaceutical supply chain, securing authenticity of an individual tablet or capsule from the manufacturer, to the distributor, and finally the pharmacy. We believe authentication is possible, even when the product is separated from packaging, making it a complement to serialization and a platform to be considered as a weapon against today’s most difficult and global challenges, such as the opioid crisis,” said Dr. James Hayward, president and CEO, Applied DNA.

The licensed pharmaceutical industry and regulators use many approaches to control counterfeiting, but it remains a very difficult task to differentiate between counterfeit and real products. Moreover, there is a lack of techniques available for providing a batch-specific molecular bar code for tablets and other solid oral dosage forms that require traceability, specificity and sensitivity to be fit for purpose.

“Counterfeit drugs represent a large and growing problem for the global pharmaceutical industry and can lead to serious illness or death. Publication of our methods and systems for molecular tagging of pharmaceuticals is a seminal development in our industrial deployment, and acceptance of our methods by scientific peers is a welcome endorsement,” said Dr. Michael Hogan, vice president, Life Sciences, Applied DNA.

“Many tablets contain lactose; thus, it was sensible to use this popular excipient in our proof of concept study. Lactose presented a good challenge to Applied DNA’s technology as it is a reducing sugar and in combination with the high temperature and high humidity storage conditions, it formed a harsh environment to test the stability of the molecular tags. The DNA tags performed exceptionally well, and were able to be easily detected after six months of storage. We believe this study shows the potential of the technology to provide traceability beginning with the powdered ingredients right through to the fully formed medicine,” said Dr. Paul Royall, Senior Lecturer in Pharmaceutics, King’s College London.

About the Institute of Pharmaceutical Science, King’s College London
The Institute of Pharmaceutical Science at King’s College London is part of the Faculty of Life Sciences & Medicine. The Institute has a flourishing research effort in the fields of drug discovery, medicines development and medicines use, and has approximately 100 registered postgraduate research students.  Through the Department of Pharmacy, the Institute provides initial education and training for pharmacists through the MPharm program and provides a range of specialist postgraduate taught courses in Pharmaceutical Science, Pharmaceutical Medicine and Clinical Pharmacy.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates.

Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its ability to continue as a going concern, its history of net losses, limited financial resources, limited market acceptance, uncertainties relating to its ability to maintain its NASDAQ listing in light of delisting notices received and its recent hearing, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018, as amended, our subsequent quarterly reports on Form 10-Q filed on February 7, 2019, May 9, 2019 and August 13, 2019, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.

Investor Contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777shurry@lhai.com
Program contact: Judy Murrah, CIO, 631-240-8819, judy.murrah@adnas.com

STONY BROOK, N.Y., October 3, 2019 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA”) (“we,” “us,” “our,” the “Company”), a leader in large-scale PCR-based DNA manufacturing, today announced  that the Nasdaq Hearings Panel (the “Panel”) , has granted Applied DNA’s request for an extension through December 31, 2019, to comply with all applicable criteria for continued listing of the Company’s securities  on The Nasdaq Capital Market (“Nasdaq”), including the minimum $1.00 bid price and $2.5 million stockholders’ equity requirements. During the extension, Applied DNA’s securities  will remain listed on Nasdaq.

“We are appreciative of the Nasdaq Hearings Panel’s decision to grant us our requested extension to evidence compliance with all applicable requirements for continued listing on Nasdaq. The management team and Board of Directors place the highest priority on our continued listing, and we want to assure all stakeholders that we continue to work diligently on executing on our compliance plan,” stated Dr. James A. Hayward, president and CEO of Applied DNA.

The Company is diligently working to comply with the minimum $1.00 bid price and $2.5 million stockholders’ equity requirements; however, there can be no assurance that the Company will be able to regain compliance with the applicable listing criteria within the period granted by the Panel.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates.Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its ability to continue as a going concern, its history of net losses, limited financial resources, limited market acceptance, uncertainties relating to its ability to maintain its NASDAQ listing in light of delisting notices received, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018, as amended, our subsequent quarterly reports on Form 10-Q filed on February 7, 2019, May 9, 2019 and August 13, 2019, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.

Investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, shurry@lhai.com